Sarina Elmariah

Dr. Sarina Elmariah


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2024 in Life
Verified
Journal Article
Open access
PDF file
RLRebecca K. Leaf
Rebecca K. Leaf
HNHetanshi Naik
Hetanshi Naik
PJPaul Yanning Jiang
Paul Yanning Jiang
SESarina Elmariah
Sarina Elmariah
PHPamela Hodges
Pamela Hodges
ADAmy Dickey
Amy Dickey
Background: Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare disorders of heme biosynthesis characterized by severe cutaneous phototoxicity. Afamelanotide, an α-melanocyte-stimulating hormone analogue, is the only approved treatment for protoporphyria and leads to increased light tolerance and improved quality of life (QoL). However, published experience with afamelanotide in the US is limited. Methods: Here, we report on all adults who received at least one dose of afamelanotide at the Massachusetts General Hospital Porphyria Center from 2021 to 2022. Changes in the time to phototoxic symptom onset, QoL, and laboratory parameters were assessed before and during treatment with afamelanotide. Results: A total of 29 patients with protoporphyria were included, 26 of whom (72.2%) received ≥2 afamelanotide implants. Among the patients who received ≥2 implants, the median time to symptom onset following sunlight exposure was 12.5 min (IQR, 5–20) prior to the initiation of afamelanotide and 120 min (IQR, 60–240) after treatment (p < 0.001). Improvements in QoL during afamelanotide treatment were measured using two QoL tools, with good correlation observed between these two instruments. Finally, we found no improvements in the median levels of metal-free erythrocyte protoporphyrin, plasma protoporphyrin, or liver biochemistries during versus prior to the initiation of afamelanotide treatment. Conclusions: This study highlights a dramatic clinical benefit of afamelanotide in relation to light tolerance and QoL in protoporphyria, albeit without improvement in protoporphyrin levels or measures of liver function.

30 August 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
SESarina Elmariah
Sarina Elmariah
NPNicole Princic
Nicole Princic
MRMegan Richards
Megan Richards
AQAamir Qureshi
Aamir Qureshi
LSLorenzo Sabatelli
Lorenzo Sabatelli
SKShawn G. Kwatra
Shawn G. Kwatra